Burning Rock Biotech (NASDAQ:BNR) Director Yusheng Han Purchases 104,650 Shares

Posted by Brenda Bartman on Jul 3rd, 2026

Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR – Get Free Report) Director Yusheng Han acquired 104,650 shares of the business’s stock in a transaction that occurred on Monday, June 22nd. The stock was bought at an average cost of $7.45 per share, for a total transaction of $779,642.50. Following the completion of the purchase, the director directly owned 18,123,196 shares in the company, valued at $135,017,810.20. This represents a 0.58% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website.

Yusheng Han also recently made the following trade(s):

On Friday, June 26th, Yusheng Han bought 24,900 shares of Burning Rock Biotech stock. The shares were bought at an average cost of $8.00 per share, with a total value of $199,200.00.
On Wednesday, June 24th, Yusheng Han purchased 250,000 shares of Burning Rock Biotech stock. The shares were bought at an average price of $8.00 per share, for a total transaction of $2,000,000.00.
On Tuesday, June 23rd, Yusheng Han purchased 5,990 shares of Burning Rock Biotech stock. The shares were bought at an average price of $7.50 per share, for a total transaction of $44,925.00.
On Tuesday, June 16th, Yusheng Han purchased 111,110 shares of Burning Rock Biotech stock. The stock was purchased at an average cost of $9.00 per share, for a total transaction of $999,990.00.
On Friday, June 12th, Yusheng Han acquired 210,000 shares of Burning Rock Biotech stock. The stock was purchased at an average price of $9.25 per share, with a total value of $1,942,500.00.
On Thursday, June 11th, Yusheng Han acquired 24,760 shares of Burning Rock Biotech stock. The stock was purchased at an average price of $8.74 per share, with a total value of $216,402.40.

Burning Rock Biotech Price Performance

NASDAQ BNR opened at $9.82 on Friday. Burning Rock Biotech Limited Sponsored ADR has a 1 year low of $3.23 and a 1 year high of $41.72. The company has a fifty day simple moving average of $12.57 and a 200 day simple moving average of $20.04. The company has a current ratio of 3.05, a quick ratio of 2.81 and a debt-to-equity ratio of 0.06. The company has a market cap of $103.31 million, a P/E ratio of -11.98 and a beta of 1.32.

Burning Rock Biotech (NASDAQ:BNR – Get Free Report) last announced its earnings results on Tuesday, June 9th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($2.29) by $2.09. The firm had revenue of $15.66 million for the quarter, compared to the consensus estimate of $19.21 million. Burning Rock Biotech had a negative net margin of 11.57% and a negative return on equity of 10.98%.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. Wall Street Zen lowered Burning Rock Biotech from a “buy” rating to a “hold” rating in a research note on Saturday, June 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Burning Rock Biotech in a research note on Monday, April 20th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Burning Rock Biotech presently has a consensus rating of “Sell”.

View Our Latest Research Report on BNR

Institutional Investors Weigh In On Burning Rock Biotech

Hedge funds and other institutional investors have recently modified their holdings of the stock. Renaissance Technologies LLC raised its holdings in Burning Rock Biotech by 13.8% in the 1st quarter. Renaissance Technologies LLC now owns 35,407 shares of the company’s stock valued at $571,000 after acquiring an additional 4,290 shares in the last quarter. Prospera Financial Services Inc grew its holdings in shares of Burning Rock Biotech by 26.0% during the 4th quarter. Prospera Financial Services Inc now owns 31,185 shares of the company’s stock worth $628,000 after purchasing an additional 6,430 shares in the last quarter. Marshall Wace LLP bought a new stake in shares of Burning Rock Biotech during the fourth quarter valued at approximately $220,000. Finally, Crcm LP increased its position in shares of Burning Rock Biotech by 13.8% during the third quarter. Crcm LP now owns 221,575 shares of the company’s stock valued at $1,917,000 after purchasing an additional 26,809 shares during the period. Institutional investors and hedge funds own 30.03% of the company’s stock.

Burning Rock Biotech Company Profile

(Get Free Report)

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.